儿童混合表型急性白血病微小残留病意义的多中心队列研究
该多中心队列研究分析经WHO分类统一诊断并接受ALL方案治疗的儿童MPAL患者,发现ALL诱导治疗使70%患者达到EOI MRD阴性(<0.01%)缓解,EOI MRD阳性可预测5年EFS(HR=6.00,p<0.001)和OS(HR=9.57,p=0.003),且多数儿童患者无需移植即可获得良好疗效。
要点
- ALL诱导治疗使70%儿童MPAL患者达到EOI MRD阴性(<0.01%)缓解。
- EOI MRD阳性预测较差的5年EFS(HR=6.00,p<0.001)和OS(HR=9.57,p=0.003)。
- 与成人不同,多数儿童MPAL患者仅用ALL化疗不移植即可获得良好疗效。
核心结论
- EOI MRD状态是儿童MPAL的重要预后因素,MRD清除越早生存越好。
- 多数儿童MPAL患者接受ALL方案化疗不移植即可获得治疗成功。
研究设计与样本
- 多中心队列研究,中心化审查,纳入经WHO分类统一诊断并接受ALL方案治疗的儿童MPAL患者。
主要发现
- ALL诱导治疗达到EOI MRD阴性(<0.01%)缓解者占70%。
- EOI MRD阳性预测5年EFS(HR=6.00,p<0.001)和OS(HR=9.57,p=0.003)。
- EOC时清除MRD的患者生存仍差于EOI MRD阴性者。
- 与成人MPAL不同,多数儿童患者仅用ALL化疗不移植即可获得良好疗效。
关键数值与推荐
- EOI MRD阴性定义为<0.01%。
- EOI MRD阳性预测5年EFS的HR=6.00(p<0.001),OS的HR=9.57(p=0.003)。
临床怎么用
- 儿童MPAL应采用ALL方案诱导治疗并监测EOI MRD。
- EOI MRD阳性提示预后不良,需考虑强化或替代策略。
- 多数儿童MPAL患者不移植仅用ALL化疗即可获得良好疗效。
局限性
- MPAL罕见,数据有限,需前瞻性试验验证和细化MRD阈值。
- 需识别预测生存差者的挽救策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The rarity of mixed phenotype acute leukemia (MPAL) has precluded adequate data to incorporate minimal residual disease (MRD) monitoring into therapy. Fluidity in MPAL classification systems further complicates understanding its biology and outcomes; this includes uncertainty surrounding the impact of shifting diagnostic requirements even between iterations of the World Health Organization (WHO) classification. Our primary objective was to address these knowledge gaps. To do so, we analyzed clinicopathologic features, therapy, MRD, and survival in a centrally-reviewed, multicenter cohort of MPAL uniformly diagnosed by the WHO classification and treated with acute lymphoblastic leukemia (ALL) regimens. ALL induction therapy achieved an EOI MRD negative (<0.01%) remission in most patients (70%). EOI MRD positivity was predictive of 5-year EFS (HR = 6.00, p < 0.001) and OS (HR = 9.57, p = 0.003). Patients who cleared MRD by EOC had worse survival compared with those EOI MRD negative. In contrast to adults with MPAL, ALL therapy without transplantation was adequate to treat most pediatric patients. Earlier MRD clearance was associated with better treatment success and survival. Prospective trials are now necessary to validate and refine MRD thresholds within the pediatric MPAL population and to identify salvage strategies for those with poor predicted survival.
引用
- Oberley MJ, Raikar SS, Wertheim GB, et al. Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study. Leukemia. 2020. PMID: 32060402. doi:10.1038/s41375-020-0741-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。